Quick Takeaways:
- Gelteq has successfully completed canine palatability trials in collaboration with Kemin Industries, evaluating products powered by its proprietary Gelteq gel-based delivery platform. The studies were designed to optimize flavor profiles and assess canine acceptance, including formulations containing naturally bitter compounds that dogs would typically reject.
- The trials showed strong canine acceptance across multiple flavor profiles and confirmed Gelteq technology’s ability to effectively mask bitter tastes while improving palatability. The findings support the platform’s potential use in veterinary pharmaceuticals, where product acceptance plays a key role in treatment compliance and therapeutic success.
- The palatability data is expected to inform future formulation development, product optimization, and study design across Gelteq’s animal health programs. The results also strengthen the company’s position in the veterinary therapeutics market, supporting ongoing discussions with pharmaceutical companies, animal health organizations, and other potential strategic partners interested in novel drug delivery technologies.
Why It Matters?
Gelteq’s canine palatability trials with Kemin confirm that its gel-based delivery platform can effectively mask bitter compounds and deliver strong acceptance across multiple flavor profiles, even with naturally unpalatable ingredients. This is a key enabler for veterinary therapeutics, where poor palatability directly undermines compliance and therapeutic outcomes, and it positions Gelteq as a differentiated delivery partner for pharma and animal health companies developing oral medications.
Source: Gelteq
